By Karen Roman
Radella Pharmaceuticals, LLC. announced the successful trial results of MD-18, its leading program to treat obesity and diabetes.
The company will start the next phase applying multiple doses of MD-18 before the end of the year, it said in a statement.
“These findings after just a single dose highlight the potential of MD-18 to deliver clinically meaningful metabolic benefits,” said Amir Tirosh, Radella’s Chief Medical Officer. “MD-18’s unique mechanism of action targets both insulin sensitivity and energy expenditure, representing a potentially transformative approach for patients with obesity and metabolic disease.”
Contact:
